Hepatic Disease in HIV-Infected Patients

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 9/4/18 (What's New)

Summary

  • AASLD/IDSA guidance panel recommends highly active DAA regimens as preferred therapy for genotype 2-6 HCV infection in HCV/HIV-coinfected patients (Table 10) (Management Guidelines)[AASLD-IDSA HCV]
  • EASL guidance panel recommends highly active DAA regimens for genotype 2-6 HCV infection in HCV/HIV coinfected patients (Table 11) (Management Guidelines)[EASL HCV]

Action required